Printer Friendly

MARTIN BARKIN NAMED CEO OF DEPRENYL RESEARCH LIMITED MORTON SHULMAN TO REMAIN CO-CHAIRMAN

 MARTIN BARKIN NAMED CEO OF DEPRENYL RESEARCH LIMITED
 MORTON SHULMAN TO REMAIN CO-CHAIRMAN
 TORONTO, Sept. 23 /PRNewswire/ -- Dr. Morton Shulman, co-chairman of Deprenyl Research Limited (TSE: DEP; NASDAQ: DEPLF), announced today that Dr. Martin Barkin, currently president and chief operating officer of the company, has been named chief executive officer, effective immediately. Dr. Shulman will remain co-chairman of the board of directors.
 "This decision reflects the emergence of Deprenyl Research Limited as a diversified pharmaceutical company," said Dr. Shulman. "The appointment of Martin Barkin as CEO is also consistent with our management succession plan."
 Dr. Barkin joined Deprenyl in March 1992 as executive vice president, and was named president and chief operating officer in June.
 Shulman said, "Deprenyl is entering a new period in its history. The entrepreneurial business approach used to launch the company is being supplanted by a greater focus on professional management and strategic planning. The company is marketing several novel products and more are expected to be launched over the next few years. Dr. Barkin's background and management style make him the ideal person to take over leadership of the company."
 In his new capacity, Dr. Barkin will direct all of Deprenyl's activities, including its planning, research, product development, and marketing programs.
 Dr. Barkin is a urologist and award-winning medical researcher. He had held a number of prominent positions in the health care community, including president and chief executive officer of Sunnybrook Health Sciences Centre in Toronto, vice chairman of the Ontario Hospital Association and president of the Ontario Council of Teaching Hospitals.
 Dr. Barkin was deputy minister of health for the province of Ontario from 1987 to 1991. He established and was secretary of the Premier's Council on Health Strategy and was chair of the Deputy Cabinet Committee on Social Policy.
 Before joining Deprenyl Research, he was a partner and national practice leader for health care for Peat Marwick Stevenson & Kellogg, where he continues to chair the health care advisory committee.
 Deprenyl Research Limited is a Canadian pharmaceutical company specializing in products for neurologic diseases, disorders of aging, other chronic conditions, and dermatology. Its common stock is traded in Canada on the Toronto Stock Exchange under the symbol DEP and in the U.S. in the NASDAQ National Market System under the symbol DEPLF.
 -0- 9/23/92
 /CONTACT: Dr. Martin Barkin, president and chief executive officer, 416-537-6241, or fax, 416-537-0258, or Dr. Morton Shulman, co-chairman (Dr. Shulman will be available to answer questions between 10 a.m. and noon on Thursday, Sept. 24), 416-537-4372, or fax, 416-537-1653, both of Deprenyl Research Limited (in Canada); or Jim Tolan, senior vice president of O'Connor Biro & Associates, 708-498-2284, or fax 708-498-3144, for Deprenyl Research Limited (in the U.S.)/
 (DEPLF) CO: Deprenyl Research Limited ST: Ontario IN: MTC SU: PER


SH -- NY071 -- 2739 09/23/92 15:14 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 23, 1992
Words:472
Previous Article:AMEX ASKS SEC FOR BLANKET APPROVAL OF INDUSTRY INDEX OPTIONS; NEW RULES WOULD ALLOW AMEX TO SERVE IMMEDIATE NEEDS OF INVESTING PUBLIC
Next Article:BASE TEN SYSTEMS ISSUES THIRD QUARTER REPORT
Topics:


Related Articles
DEPRENYL RESEARCH CHAIRMAN ISSUES STATEMENT ON SELL ADVISORY
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL RESEARCH ELECTS MARTIN BARKIN PRESIDENT, CHIEF OPERATING OFFICER AND DIRECTOR
DEPRENYL RESEARCH NOTES NO CHANGE IN COMPANY TO ACCOUNT FOR CURRENT PRESSURES ON SHARE PRICE
DEPRENYL ANNOUNCES AGREEMENT TO ACQUIRE CONTROL OF LIPOPHARM
DEPRENYL ACQUIRES CONTROL OF QUEBEC-BASED LIPOPHARM INC.
DEPRENYL RESEARCH ANNOUNCES FINAL PROSPECTUS OF BONE HEALTH INC.
DEPRENYL RESEARCH LIMITED ANNOUNCES NEW APPOINTMENTS
DEPRENYL RESEARCH LIMITED ANNOUNCES RETIREMENT OF DR. MORTON SHULMAN

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters